For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.

Amgen - Recent Press Releases
10/23/14Amgen To Webcast 2014 Business Review Meeting On October 28Printer Friendly Version
10/23/14Amgen Announces Webcast of 2014 Third Quarter Financial ResultsPrinter Friendly Version
10/21/14Amgen Statement Regarding Third Point InvestmentPrinter Friendly Version
10/17/14Amgen Announces Appointment Of R. Sanders Williams To Board Of DirectorsPrinter Friendly Version
10/17/14Amgen Announces 2014 Fourth Quarter DividendPrinter Friendly Version
10/17/14Amgen Files Lawsuit Against Sanofi And Regeneron For Patent InfringementPrinter Friendly Version
10/09/14Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic LeukemiaPrinter Friendly Version
10/08/14Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque PsoriasisPrinter Friendly Version
10/01/14The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High CholesterolPrinter Friendly Version
10/01/14Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And VenereologyPrinter Friendly Version